334 related articles for article (PubMed ID: 9002775)
21. Neuroendocrine tumors and somatostatin: imaging techniques.
de Herder WW; Kwekkeboom DJ; Valkema R; Feelders RA; van Aken MO; Lamberts SW; van der Lely AJ; Krenning EP
J Endocrinol Invest; 2005; 28(11 Suppl International):132-6. PubMed ID: 16625862
[TBL] [Abstract][Full Text] [Related]
22. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
Kwekkeboom DJ; Lamberts SW; Habbema JD; Krenning EP
J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
[TBL] [Abstract][Full Text] [Related]
24. Comparison of somatostatin analogue and metaiodobenzylguanidine scintigraphy for the detection of carcinoid tumours.
Nocaudie-Calzada M; Huglo D; Carnaille B; Proye C; Marchandise X
Eur J Nucl Med; 1996 Nov; 23(11):1448-54. PubMed ID: 8854840
[TBL] [Abstract][Full Text] [Related]
25. Utility of thallium-201 and iodine-123 metaiodobenzylguanidine in the scintigraphic detection of neuroendocrine neoplasia.
Montravers F; Coutris G; Sarda L; Mensch B; Talbot JN
Eur J Nucl Med; 1993 Nov; 20(11):1070-7. PubMed ID: 8287875
[TBL] [Abstract][Full Text] [Related]
26. [Detection of neural crest tumors by 123I-MIBG scintigraphy].
Ikekubo K; Hino M; Ootsuka H; Ito H; Yamaguchi H; Dan Y; Masui Y; Bito S; Ohta K; Saiki Y
Kaku Igaku; 1994 Nov; 31(11):1357-64. PubMed ID: 7837704
[TBL] [Abstract][Full Text] [Related]
27. MIBG and radiolabeled octreotide in neuroendocrine tumors.
Hoefnagel CA
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):137-9. PubMed ID: 9002773
[TBL] [Abstract][Full Text] [Related]
28. Pentavalent technetium-99m (V)-DMSA uptake in a pheochromocytoma in a patient with Sipple's syndrome.
Adams BK; Fataar A; Byrne MJ; Levitt NS; Matley PJ
J Nucl Med; 1990 Jan; 31(1):106-8. PubMed ID: 1967305
[TBL] [Abstract][Full Text] [Related]
29. Nuclear medicine applications for neuroendocrine tumors.
Chatal JF; Le Bodic MF; Kraeber-Bodéré F; Rousseau C; Resche I
World J Surg; 2000 Nov; 24(11):1285-9. PubMed ID: 11038195
[TBL] [Abstract][Full Text] [Related]
30. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas.
van der Harst E; de Herder WW; Bruining HA; Bonjer HJ; de Krijger RR; Lamberts SW; van de Meiracker AH; Boomsma F; Stijnen T; Krenning EP; Bosman FT; Kwekkeboom DJ
J Clin Endocrinol Metab; 2001 Feb; 86(2):685-93. PubMed ID: 11158032
[TBL] [Abstract][Full Text] [Related]
31. Scintiscans and carcinoid tumors.
Carnaille B; Nocaudie M; Pattou F; Huglo D; Deveaux M; Marchandise X; Proye C
Surgery; 1994 Dec; 116(6):1118-21; discussion 1121-2. PubMed ID: 7985096
[TBL] [Abstract][Full Text] [Related]
32. 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
Balogova S; Talbot JN; Nataf V; Michaud L; Huchet V; Kerrou K; Montravers F
Eur J Nucl Med Mol Imaging; 2013 Jun; 40(6):943-66. PubMed ID: 23417499
[TBL] [Abstract][Full Text] [Related]
33. Imaging advances in the diagnosis of endocrine neoplasia.
Scott BA; Gatenby RA
Curr Opin Oncol; 1998 Jan; 10(1):37-42. PubMed ID: 9466483
[TBL] [Abstract][Full Text] [Related]
34. Factor analysis of dynamic series (FADS) in somatostatin receptor imaging.
Kolesnikov-Gauthier H; Huglo D; Nocaudie M; Marchandise X
J Nucl Med; 1999 Jan; 40(1):33-9. PubMed ID: 9935053
[TBL] [Abstract][Full Text] [Related]
35. Usefulness of Somatostatin Receptor Scintigraphy (Tc-[HYNIC, Tyr3]-Octreotide) and 123I-Metaiodobenzylguanidine Scintigraphy in Patients with SDHx Gene-Related Pheochromocytomas and Paragangliomas Detected by Computed Tomography.
Michałowska I; Ćwikła JB; Pęczkowska M; Furmanek MI; Buscombe JR; Michalski W; Prejbisz A; Szperl M; Malinoc A; Moczulski D; Szutkowski Z; Kawecki A; Antoniewicz J; Pęczkowski P; Lewczuk A; Otto M; Cichocki A; Bednarek-Tupikowska G; Kabat M; Janaszek-Sitkowska H; Przybyłowska K; Janas J; Neumann HP; Januszewicz A
Neuroendocrinology; 2015; 101(4):321-30. PubMed ID: 25791839
[TBL] [Abstract][Full Text] [Related]
36. [Pre- and intraoperative localization of neuroendocrine tumors].
Adams S; Baum RP; Adams M; Wenisch H; Schumm-Draeger PM; Encke A; Usadel KH; Hör G
Acta Med Austriaca; 1997; 24(2):81-6. PubMed ID: 9273812
[TBL] [Abstract][Full Text] [Related]
37. Imaging of carcinoid tumors with iodine-123 metaiodobenzylguanidine.
Bomanji J; Levison DA; Zuzarte J; Britton KE
J Nucl Med; 1987 Dec; 28(12):1907-10. PubMed ID: 3681447
[TBL] [Abstract][Full Text] [Related]
38. [Radionuclide imaging of neurendocrine tumors: biological basis and diagnostic results].
Genovese EA; Mallardo V; Rossi M; Vaccaro A; Raucci A; Della Vecchi N; Romano G; Califano T; Schillirò F
Recenti Prog Med; 2013; 104(7-8):340-4. PubMed ID: 24042404
[TBL] [Abstract][Full Text] [Related]
39. Iodine-131 metaiodobenzylguanidine scintigraphy of carcinoid tumors.
Feldman JM; Blinder RA; Lucas KJ; Coleman RE
J Nucl Med; 1986 Nov; 27(11):1691-6. PubMed ID: 3772504
[TBL] [Abstract][Full Text] [Related]
40. Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide.
Forssell-Aronsson E; Fjälling M; Nilsson O; Tisell LE; Wängberg B; Ahlman H
J Nucl Med; 1995 Jan; 36(1):7-12. PubMed ID: 7799086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
